Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The optimization of antiviral RNAs targeting HIV for use in gene therapy
FY 2016-17
Summary
Human Immunodeficiency Virus (HIV) affects 37.2 million people and remains one of the top 10 causes of death worldwide. Although the use of antiretroviral drugs has improved the life expectancy of those infected with HIV, it is likely never to be curative due to its inability to eliminate the virus. Furthermore, the high cost of antiretroviral therapy and well- characterized side effects highlight the need for an alternative therapy or even a cure for HIV. A potential cure that is currently being researched is gene therapy. In such an approach, patients cells are modified to express a gene or genes that can inhibit HIV replication. One type of gene that can be used in this therapy is antiviral RNA. Numerous steps in the HIV replication cycle have been exploited for the development of therapeutic antiviral RNAs with several molecules advancing into clinical trials. Since HIV has the ability to mutate rapidly to resist drug therapy, a combination of therapeutic RNA molecules is required to effectively inhibit the virus. However, there are limited data available on the use of a combination of therapeutic RNAs in order to treat HIV. Our research aims to identify optimal candidates, in terms of efficacy and safety, from the major classes of antiviral RNAs that can target HIV. We will then characterize the effects of combining these different therapeutic molecules in order to find an optimal combination for use in HIV gene therapy. Our research will be crucial for the future development of combinatorial RNA gene therapy and will help accelerate therapies into the clinic that have the potential to cure HIV infection.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367099
Name
Del Corpo Olivier
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The optimization of antiviral RNAs targeting HIV for use in gene therapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Toxicity; Hiv Gene Therapy; Immunology; Microbiology; Pharmacology; Rna Interference; Rna Therapy; Short Hairpin Rnas; U1 Interference Rnas; Virology
Abstract
Human Immunodeficiency Virus (HIV) affects 37.2 million people and remains one of the top 10 causes of death worldwide. Although the use of antiretroviral drugs has improved the life expectancy of those infected with HIV, it is likely never to be curative due to its inability to eliminate the virus. Furthermore, the high cost of antiretroviral therapy and well- characterized side effects highlight the need for an alternative therapy or even a cure for HIV. A potential cure that is currently being researched is gene therapy. In such an approach, patients cells are modified to express a gene or genes that can inhibit HIV replication. One type of gene that can be used in this therapy is antiviral RNA. Numerous steps in the HIV replication cycle have been exploited for the development of therapeutic antiviral RNAs with several molecules advancing into clinical trials. Since HIV has the ability to mutate rapidly to resist drug therapy, a combination of therapeutic RNA molecules is required to effectively inhibit the virus. However, there are limited data available on the use of a combination of therapeutic RNAs in order to treat HIV. Our research aims to identify optimal candidates, in terms of efficacy and safety, from the major classes of antiviral RNAs that can target HIV. We will then characterize the effects of combining these different therapeutic molecules in order to find an optimal combination for use in HIV gene therapy. Our research will be crucial for the future development of combinatorial RNA gene therapy and will help accelerate therapies into the clinic that have the potential to cure HIV infection.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Del Corpo, Olivier
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~